-4.56 (-8.13, -1.00) 0.01 rs1014290 NA 3.59 (0.67, 6.51) 0.02 rs733175 NA Lyngdoh ADDIN OR 1.40 (1.07, 1.84) 0.02 EN.CITE (male) Lifetime anxiety 2013 Switzerland 3,716/660 rs6855911 in SLC2A9 3.2% disorders OR 0.97 (0.80, 1.17) 0.73 (female) Lyngdoh ADDIN OR 1.42 (0.99, 2.03) 0.06 EN.CITE (male) Current anxiety 2013 Switzerland 3,716/370 rs6855911 in SLC2A9 3.2% disorders OR 0.84 (0.66, 1.06) 0.14 (female) Overall P<0.05 4 SNPs in SCL2A9 Houlihan ADDIN -0.10 (NA, NA) rs733175 EN.CITE European NO ADDIN Memory -0.07 (NA, NA) 0.01 β rs1014290 2010 (Population 1: 1,091 NA performance EN.CITE LBC1936) -0.07 (NA, NA) 0.01 rs6449213 -0.07 (NA, NA) 0.01 rs6449213 (discordance in Overall P>0.05 statistical 4 SNPs in SCL2A9 Houlihan ADDIN significance) EN.CITE European -0.03 (NA, NA) Memory 0.27 β rs733175 2010 (Population 2: 1,066 NA performance ET2DS) -0.04 (NA, NA) 0.22 rs1014290
rs1014290 NA -4.56 (-8.13, -1.00) 0.01 rs733175 NA 3.59 (0.67, 6.51) 0.02 Lyngdoh ADDIN EN.CITE 2013 Switzerland 3,716/660 Lifetime anxiety disorders rs6855911 in SLC2A9 3.2% OR (male) 1.40 (1.07, 1.84) 0.02 OR (female) 0.97 (0.80, 1.17) 0.73 Lyngdoh ADDIN EN.CITE 2013 Switzerland 3,716/370 Current anxiety disorders rs6855911 in SLC2A9 3.2% OR (male) 1.42 (0.99, 2.03) 0.06 OR (female) 0.84 (0.66, 1.06) 0.14 Houlihan ADDIN EN.CITE 2010 European (Population 1: LBC1936) 1,091 Memory performance 4 SNPs in SCL2A9 NA β Overall P<0.05 NO ADDIN EN.CITE (discordance in statistical significance) rs733175 -0.10 (NA, NA) rs1014290 -0.07 (NA, NA) 0.01 rs6449213 -0.07 (NA, NA) 0.01 rs6449213 -0.07 (NA, NA) 0.01 Houlihan ADDIN EN.CITE 2010 European (Population 2: ET2DS) 1,066 Memory performance 4 SNPs in SCL2A9 NA β Overall P>0.05 rs733175 -0.03 (NA, NA) 0.27 rs1014290 -0.04 (NA, NA) 0.22
Supplementary%20material_v7%20-%20Final-2.docx